C****a
发帖数: 1639 | | C****a
发帖数: 1639 | 2 The biotechnology giant’s first-quarter profits beat expectations on growth
of its multiple sclerosis drug Tysabri, and at the same time the company
gave important new data on its oral multiple sclerosis drug BG-12.
Biogen said the drug cut relapses 49% after two years, compared to placebo,
with an annual relapse reduction rate of 53%. It also reduced the
progression of disability by 38%. In comparison, Teva Pharmaceutical
Industries (TEVA) last week said its oral multiple sclerosis drug reduced
the annual relapse rate by 23% and disability progression fell 36%.
Investors wasted no time in reacting. Biogen’s shares surged 20% in early
trading, while Teva’s ADRs fell 6.3%.
Biogen reported first quarter earnings of $1.43 per share, two cents a share
better than the Thomson Reuters consensus of $1.41, on revenues of $1.2
billion.
Sales of Tysabri have been crimped by concerns over its association with a
potentially deadly brain infection known as progressive multifocal
leukoencephalopathy, or PML. But Biogen hopes to introduce a test that can
screen patients and identify which are at higher risk of developing PML. | H******k
发帖数: 690 | | r***o
发帖数: 78 | |
|
